12.96
price down icon0.46%   -0.06
after-market Dopo l'orario di chiusura: 12.90 -0.06 -0.46%
loading
Precedente Chiudi:
$13.02
Aprire:
$12.88
Volume 24 ore:
1.84M
Relative Volume:
0.75
Capitalizzazione di mercato:
$325.06M
Reddito:
$82.71M
Utile/perdita netta:
$-102.24M
Rapporto P/E:
-3.5313
EPS:
-3.67
Flusso di cassa netto:
$-76.57M
1 W Prestazione:
-5.54%
1M Prestazione:
+167.77%
6M Prestazione:
+21.12%
1 anno Prestazione:
-14.40%
Intervallo 1D:
Value
$12.73
$13.64
Intervallo di 1 settimana:
Value
$12.73
$13.93
Portata 52W:
Value
$3.42
$18.15

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
Nome
Urogen Pharma Ltd
Name
Telefono
972 9 770 7601
Name
Indirizzo
9 HA'TA'ASIYA ST, RA'ANANA
Name
Dipendente
234
Name
Cinguettio
@UroGenPharma
Name
Prossima data di guadagno
2025-03-10
Name
Ultimi documenti SEC
Name
URGN's Discussions on Twitter

Confronta URGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
URGN
Urogen Pharma Ltd
12.96 325.06M 82.71M -102.24M -76.57M -3.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-16 Aggiornamento H.C. Wainwright Neutral → Buy
2025-05-22 Downgrade H.C. Wainwright Buy → Neutral
2025-04-16 Iniziato Scotiabank Sector Outperform
2025-02-19 Ripresa Ladenburg Thalmann Buy
2024-08-22 Iniziato Guggenheim Buy
2023-02-08 Downgrade Jefferies Buy → Hold
2022-04-27 Iniziato Berenberg Buy
2020-04-16 Reiterato H.C. Wainwright Buy
2020-04-13 Reiterato H.C. Wainwright Buy
2020-01-09 Iniziato National Securities Neutral
2019-05-30 Iniziato JP Morgan Neutral
2019-05-29 Iniziato Goldman Neutral
2019-01-29 Iniziato H.C. Wainwright Buy
2018-11-08 Ripresa Jefferies Buy
2018-04-04 Aggiornamento Raymond James Mkt Perform → Outperform
2018-01-02 Iniziato Ladenburg Thalmann Buy
2017-11-15 Reiterato Oppenheimer Outperform
2017-11-15 Downgrade Raymond James Outperform → Mkt Perform
Mostra tutto

Urogen Pharma Ltd Borsa (URGN) Ultime notizie

pulisher
Jun 19, 2025

Urogen Pharma (NASDAQ:URGN) Short Interest Down 29.9% in May - Defense World

Jun 19, 2025
pulisher
Jun 19, 2025

HC Wainwright Decreases Earnings Estimates for Urogen Pharma - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - FinancialContent

Jun 18, 2025
pulisher
Jun 18, 2025

UroGen Pharma Ltd (NASDAQ: URGN) Stock: A Value Hunter’s Investment? - Stocksregister

Jun 18, 2025
pulisher
Jun 17, 2025

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

UroGen Pharma (NASDAQ:URGN) Upgraded to “Buy” at HC Wainwright - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 16, 2025

UroGen Investor Drops Cancer Drug Suit Following FDA Approval - Bloomberg Law News

Jun 16, 2025
pulisher
Jun 16, 2025

Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about ... - Eagle-Tribune

Jun 16, 2025
pulisher
Jun 16, 2025

Investors who lost money on UroGen Pharma Ltd.(URGN) should - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class Action - ACCESS Newswire

Jun 16, 2025
pulisher
Jun 16, 2025

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Jun 16, 2025
pulisher
Jun 16, 2025

HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025URGN - PR Newswire

Jun 16, 2025
pulisher
Jun 15, 2025

Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Scotiabank Raises UroGen Pharma (NASDAQ:URGN) Price Target to $47.00 - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

UroGen Pharma (NASDAQ:URGN) Shares Gap Up After Analyst Upgrade - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Kilgore News Herald

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Victoria Advocate

Jun 13, 2025
pulisher
Jun 13, 2025

Goldman Sachs Increases Price Target for UroGen Pharma (URGN) Af - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma Gains Amid Analyst Ratings in Biopharma Sector Russell 1000 - Kalkine Media

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma price target raised to $31 from $10 at Oppenheimer - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote - insights.citeline.com

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Receives Price Target Boost to $31 After Zusduri Approval | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Sees Price Target Doubled by Scotiabank | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Opt - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Soars After FDA Approval and Price Target B - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Why Is UroGen Pharma Stock Trading Higher On Friday?UroGen Pharma (NASDAQ:URGN) - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Optimism | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Stock Outlook: Guggenheim Raises Price Target | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20 - Asianet Newsable

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen continues to climb after bladder cancer drug approval - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Transcript : UroGen Pharma Ltd.Special Call - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote - Fierce Pharma

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at D. Boral Capital - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma stock soars as FDA approves Zusduri despite negative panel vote - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves UroGen Pharma’s bladder cancer treatment - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma stock price target raised to $47 from $23 at Scotiabank - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Guggenheim Boosts UroGen Pharma (URGN) Price Target Following FDA Approval | URGN Stock News - GuruFocus

Jun 13, 2025

Urogen Pharma Ltd Azioni (URGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):